Lilly & Novo Nordisk Race for India's Obesity Drug Market

Pharma giants Eli Lilly and Novo Nordisk are vying for dominance in Indias burgeoning obesity drug market, with Lillys Mounjaro currently leading the pack. The market is projected to surge from seventy million to one billion dollars in just two years, driven by Indias growing overweight and obese population. Mounjaros success is attributed to its significant weight loss claims and early launch, while Novos Wegovy has seen a price drop, making it more accessible. Both companies are expanding their reach through partnerships and marketing efforts, with Lilly enjoying longer patent protection. As generics approach, the focus shifts to quality, affordability, and building trust in this crucial market.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.